- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04775498
Psychoeducation Programmes - Patients With Bipolar Disorder (AppEduc-BD)
Non-inferiority Study Comparing Two Psychoeducation Programmes (Mobile Application Versus Face-to-face Psychoeducation Group) in a Population of Patients With Bipolar Disorder
Study Overview
Status
Intervention / Treatment
Detailed Description
Bipolar disorder (affecting 3 to 5% of French population) is characterized by the recurrence of severe symptomatic periods (depression, mania, hypomania) and interepisodic periods characterized by the persistence of residual symptoms, impaired psychosocial functioning and quality of life. The combination of psychosocial strategies with drug treatment is associated with an improvement in the prognosis of the disease. Among these complementary strategies, psychoeducation has been shown to be effective in reducing the risk of recurrence, the length of hospital stays and improving compliance. It improves an individual's understanding and knowledge of their disorder and its various treatments. Despite its effectiveness, psychoeducation for bipolar disorder remains relatively scarcely applied in France due to a limited healthcare offer (44 available programmes labeled by the Regional Health Agencies in 2017).
In recent years, a significant number of smartphone applications have been developed in the field of mental health. To date, none of these applications has proven effective in patients with bipolar disorder. In this context, the Institute of Neuroscience of Barcelona has developed a "SIMPLe" application to assess and record a subject's symptoms and deliver personalized psychoeducation. In terms of efficacy, a study has shown the interest of this application in improving biological rhythms, thereby reducing the risk of relapse and improving psychosocial functioning and the quality of life of patients suffering from bipolar disorder in remission phase. This application has been translated and adapted into French as part of a partnership with the Barcelona Institute of Neuroscience. However, the benefits of this type of application in terms of effectiveness, accessibility or reduction of health costs have never been studied in comparison to face-to-face psychoeducation programmes. This research project therefore represents a real opportunity to evaluate for the first time the effectiveness of an application allowing the delivery of personalized psychoeducation in comparison to a face-to-face group psychoeducation program (reference treatment for relapse prevention).
The SIMPLe app includes 5 daily questions (mood, energy, sleep, irritability, medication adherence) that will assess different areas associated with bipolar disorder. The user will also receive a weekly test to determine the presence and intensity of depressive or manic symptoms. Daily and personalized psychoeducation messages (adapted to the answers to the tests carried out) will be sent to the user by notifications. The app contains a bank of around 400 psychoeducational messages, based on Prof. Vieta and Dr Colom's Psychoeducation Manual for Bipolar Disorders.
Eligible patients, after obtaining their consent, will be randomized (i) either in the face-to-face psychoeducation group which will consist of the participation by the patients in all the sessions of a therapeutic education program (labeled and controlled by their Regional Health Agency) of the investigator center, (ii) or in the SIMPLe application group and will benefit from access to the application via a code that will be sent to them.
Three additional visits to the usual care are planned (assessment visit, 6 months and 12 months). At each visit, patients must complete questionnaires (CSRI, YMRS, MADRS, FAST, MARS, WHOQOL-BREF and EQ-5D).
The hypothesis formulated by the investigator is that a psychoeducational strategy using the SIMPLe smartphone application has an effect comparable to participation in a face-to-face psychoeducation group, in term of the recurrence prevention in a sample of stabilized patients with bipolar disorder (at 12 months). The recurrence rate is defined by the percentage of patients having presented a mood episode of bipolar disorder, namely a major depressive episode, manic or hypomanic episode, according to the criteria of DSM-5 and on the basis of the judgment of the clinician since the beginning of the intervention.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lise Laclautre
- Phone Number: 33.4.73.754.963
- Email: promo_interne_drci@chu-clermontferrand.fr
Study Locations
-
-
-
Bordeau, France, 33076
- Not yet recruiting
- CH Charles Perrens
-
Clermont-Ferrand, France, 63000
- Recruiting
- CHU - Gabriel Montpied
-
Contact:
- Samalin Ludovic
- Email: lsamalin@chu-clermontferrand.fr
-
Contact:
- Pierre-Michel Llorca
- Email: pmllorca@chu-clermontferrand.fr
-
Montpellier, France, 34295
- Not yet recruiting
- CHU - Hôpital Lapeyronie
-
Contact:
- Emilie Olié
- Email: e-olie@chu-montpellier.fr
-
Nantes, France, 44000
- Not yet recruiting
- CHU
-
Contact:
- Anne Sauvaget
- Email: anne.oiry@univ-nantes.fr
-
Nîmes, France, 30029
- Not yet recruiting
- CHU - Hôpital Universitaire Carémeau
-
Contact:
- Mocrane Abbar
- Email: mocrane.abbar@chu-nimes.fr
-
Paris, France, 75010
- Not yet recruiting
- APHP - Hôpital Fernand-Widal
-
Contact:
- Sébastien Etain
- Email: bruno.etain@inserm.fr
-
Paris, France, 75674
- Not yet recruiting
- CH Saint-Anne
-
Contact:
- Philip Gorwood
-
Paris, France, 94010
- Not yet recruiting
- APHP - Centre Hospitalier Henri Mondor
-
Pontarlier, France, 25304
- Not yet recruiting
- CHI HC site rives du Doubs Pontarlier
-
Contact:
- Andreea Marinescu
-
Toulouse, France, 31059
- Not yet recruiting
- CHU - Hôpital de Psychiatrie
-
Contact:
- Antoine Yrondi
- Email: yrondi.a@chu-toulouse.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Suffering from bipolar disorder (type 1 or 2) according to DSM-5 criteria
- Not presenting a mood episode according to DSM-5 criteria
- Stable for at least 1 month with scores on YMRS < 8 and MADRS < 8
- Owning a smartphone
- Agreeing to attend group psychoeducation sessions
- Having no problem understanding fluent French
- Having given free and informed consent and signed the consent to participate in the study
- Available for 12 onth follow-up
Exclusion Criteria:
- Not having a smartphone compatible with the SIMPLe application
- Cannot attend psychoeducation group sessions on a regular basis
- Not having given their consent to participate in the study or unable to give their informed consent
- Not affiliation with a social security scheme
- Having a legal protection measure (safeguard of justice or guardianship)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Face-to-face psychoeducation group
The group of face-to-face psychoeducation or standard intervention will consist of the participation by the patients include in all the sessions of a therapeutic education programme of the investigator center.
|
All of the investigation centers participating in this study have a psychoeducation programme on bipolar disorders labeled and monitored by their Regional Health Agency.
For this, he must respect the decree of January 14, 2015 relating to the specifications of therapeutic education programs for the patient.
Patients will be receive by an investigator, for inclusion and baseline evaluation and at 6 and 12 months after inclusion.
During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
|
Experimental: SIMPLe mobile application
The experimental intervention consists of the use of the SIMPLe application during 1 year: answers of 5 daily questions and to the weekly questions.
Moreover, daily and personalized psychoeducation messages (adapted to the answers to the tests carried out) will be sent to user by notifications.
|
The experimental intervention consists of 12 months use SIMPLe smartphone application who has been developed by the Barcelona Institute of neuroscience.
The purpose of this application is to deliver individualized psychoeducation messages to the patient's clinical condition.
The psychoeducational messages correspond to the contents of the different modules and sessions carried out in face-to-face psychoeducation groups (Colomm & Vieta ; 2015).
Patients will be receive by an investigator for inclusion and baseline evaluation, at 6 and 12 months after inclusion.
During this meeting, investigator and patient will be complete 7 questionnaires (about disease, treatment observance and quality of life), investigator will collect treatment, style life and adverse event(s).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence rate
Time Frame: 12 months after inclusion
|
Measure the difference of recurrence rate (defined by the percentage of patients having presented a mood episode of bipolar disorder, namely a major depressive episode, manic or hypomanic episode, according to the criteria of DSM-5 and on the judgment of the clinician since the beginning of the intervention) between patients who participated to face-to-face psychoeducation group and patients who use SIMPLe application
|
12 months after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospitalization number
Time Frame: 6 months after inclusion
|
Measure the difference of number and duration of hospitalization between patients who participated to face-to-face psychoeducation group and patients who use SIMPLe application
|
6 months after inclusion
|
Hospitalization number
Time Frame: 12 months after inclusion
|
Measure the difference of number and duration of hospitalization between patients who participated to face-to-face psychoeducation group and patients who use SIMPLe application
|
12 months after inclusion
|
Maniac and depressive symptomatology intensity
Time Frame: 6 months after inclusion.
|
Measure the difference of maniac and depressive symptomatology intensity between patients who participated to face-to-face psychoeducation group and patients who use SIMPLe application.
These measures are based on YMRS (for maniac symptomatology) questionnaire.
|
6 months after inclusion.
|
Maniac and depressive symptomatology intensity
Time Frame: 12 months after inclusion.
|
Measure the difference of maniac and depressive symptomatology intensity between patients who participated to face-to-face psychoeducation group and patients who use SIMPLe application.
These measures are based on YMRS (for maniac symptomatology) questionnaire.
|
12 months after inclusion.
|
Maniac and depressive symptomatology intensity
Time Frame: 6 months after inclusion.
|
Measure the difference of maniac and depressive symptomatology intensity between patients who participated to face-to-face psychoeducation group and patients who use SIMPLe application.
These measures are based on MADRS (for depressive symptomatology) questionnaires.
|
6 months after inclusion.
|
Maniac and depressive symptomatology intensity
Time Frame: 6 months after inclusion.
|
Measure the difference of medication compliance between patients who participated to face-to-face psychoeducation group and patients who use SIMPLe application.
This measure is based on MARS (Medication Adherence Report Scale) questionnaire.
|
6 months after inclusion.
|
Medication compliance
Time Frame: 12 months after inclusion.
|
Measure the difference of medication compliance between patients who participated to face-to-face psychoeducation group and patients who use SIMPLe application.
This measure is based on MARS (Medication Adherence Report Scale) questionnaire.
|
12 months after inclusion.
|
Psychosocial functioning
Time Frame: 6 months after inclusion.
|
Measure the difference of psychosocial functioning between patients who participated to face-to-face psychoeducation group and patients who use SIMPLe application.
This measure is based on FAST (Functional Analysis Screening Tool ) questionnaire.
|
6 months after inclusion.
|
Psychosocial functioning
Time Frame: 12 months after inclusion.
|
Measure the difference of psychosocial functioning between patients who participated to face-to-face psychoeducation group and patients who use SIMPLe application.
This measure is based on FAST (Functional Analysis Screening Tool ) questionnaire.
|
12 months after inclusion.
|
Evaluation of Quality of life
Time Frame: 6 months ater inclusion
|
Measure the difference of quality of life between patients who participated to face-to-face psychoeducation group and patients who use SIMPLe application.
This measure is based on WHOQOL-BREF (World Health Organization Quality of Life) questionnaire.
|
6 months ater inclusion
|
Evaluation of Quality of life
Time Frame: 12 months ater inclusion
|
Measure the difference of quality of life between patients who participated to face-to-face psychoeducation group and patients who use SIMPLe application.
This measure is based on WHOQOL-BREF (World Health Organization Quality of Life) questionnaire.
|
12 months ater inclusion
|
Cost efficiency
Time Frame: 12 month after inclusion
|
Cost efficiency evaluation of SIMPLe application using CSRI (Client Service Receipt Inventory) questionnaire
|
12 month after inclusion
|
Cost / utility ratio
Time Frame: 12 month after inclusion
|
Evaluation of cost / utility ratio of SIMPLe application using the EQ-5D (EuroQol 5 Dimensions) questionnaire.
|
12 month after inclusion
|
Qualitative analysis
Time Frame: 12 months after inclusion
|
Some patients of SIMPLe application group (4 womens and 4 mens < 30 years, 4 womens and 4 mens 30 to 50 years and 4 womens and 4 mens > 50 years) will participate in an individual interview.
These semi-structured individual interviews will be carried out by a psychologist.
During these interviews the perception and use of the SIMPLe application by patients will be gathered (both positive opinions and negative criticisms and possible obstacles to its use).
|
12 months after inclusion
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PREPS 2017 SAMALIN
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder Type I or II (According to DSM-5)
-
University Hospital, Strasbourg, FranceUnknownBipolar Disorder I | Bipolar Disorder II | Rapid Cycling Bipolar Disorder(DSM-IV-TR)France
-
Medtronic Cardiac Rhythm and Heart FailureCompletedClass I or II Indication for Implantation of a Single Chamber Ventricular Pacemaker According to ACC/AHA/HRS 2001 Guidelines and Any National GuidelinesUnited States, Netherlands, Japan, Serbia, Spain, Greece, Canada, India, Denmark, Czechia, South Africa, Malaysia, Austria, United Kingdom, Hungary, China, Australia, France, Italy
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
New York State Psychiatric InstituteCompleted
-
Eli Lilly and CompanyCompleted
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Wayne State UniversityUnknownBipolar Disorder I | Bipolar Disorder II | Bipolar Affective Disorder, Currently in RemissionUnited States
-
Stanford UniversityNot yet recruitingObesity | Metabolic Syndrome | Bipolar Disorder | Bipolar and Related Disorders | Bipolar Depression | Weight Gain | Bipolar I Disorder | Ketogenic Dieting | Bipolar Disorder I | Bipolar II Disorder | Psychotropic Agents Causing Adverse Effects in Therapeutic Use | Brain Metabolic Disorder | Bipolar Disorder, Type... and other conditionsUnited States
-
Nantes University HospitalCR2TI, INSERM, UMR1064RecruitingBipolar Disorder I | Bipolar Disorder II | Schizoaffective Disorder, Depressive TypeFrance
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingBipolar Disorder | Cannabis Use | Bipolar I Disorder | Cannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, Severe | Bipolar II Disorder | Schizoaffective Disorder, Bipolar TypeUnited States
Clinical Trials on Face-to-face psychoeducation group
-
Chinese University of Hong KongCompleted
-
Uppsala UniversityCompleted
-
Maastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknownIrritable Bowel SyndromeNetherlands
-
Marmara UniversityCompleted
-
Inonu UniversityActive, not recruiting
-
Shahid Beheshti University of Medical SciencesUnknownArrythmiaIran, Islamic Republic of
-
Saglik Bilimleri Universitesi Gulhane Tip FakultesiCompleted
-
University of ValenciaCompletedLearning | StudentsSpain
-
University of Sao PauloRecruiting
-
Abant Izzet Baysal UniversityNot yet recruiting